The Leucine-Rich Repeat Kinase 2 (LRRK2) is implicated in autosomal dominant Parkinson's disease (PKD). An inhibitor for the leucine-rich repeat kinase 2 (LRRK2) is in pre-clinical development for potential use in treating Parkinson's disease. Patients with PKD have cognitive impairments which develop alongside the typical motor symptoms but a full characterisation of the neurocognitive phenotype of PKD patients with LRRK2 mutation is currently lacking. This observational study conducted on a single visit will assess the phenotypic neurocognitive abnormalities of PKD patients with the LRRK2 mutation with the aim of identifying potential PD endpoints related to the LRRK2 mutation for future Phase I or II clinical trials of LRRK2 inhibitors.
Name: Healthy
Description: Healthy VolunteersType: GeneticHealthy Controls
Name: PKD Patients
Description: PKS PatientsType: GeneticPKD Patients
Description: Action Selection, Tower of London, Shape manipulation, Emotional processing
Measure: Imaging (fMRI) Time: Day 1Description: Mini Mental State Examination (MMSE), Reward/punishment learning score, Task-set switching, Attentional set-shifting score, Spatial working memory score
Measure: Cognition Time: Day 1Description: Sniffin' sticks
Measure: Olfactory Time: Day 1Description: Unified Parkinson's Disease Rating Scale (UPDRS), Beck Depression Inventory (BDI), Parkinson's Disease Sleep Scale (PDSS), Nonmotor Symptoms Questionnaire, Questionnaire for Impulsive-Compulsive Disorders in Parkinson's Disease, Caffeine/Smoking Questionnaire
Measure: Motor / Other Time: Day 1Allocation: Non-Randomized
Single Group Assignment
There is one SNP
- Confirmed ascertainment as having the G2019S mutation in the LRRK2 gene. --- G2019S ---